Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL
Leukemia, Lymphoma
About this trial
This is an interventional treatment trial for Leukemia focused on measuring Waldenstrom macroglobulinemia, refractory chronic lymphocytic leukemia, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent small lymphocytic lymphoma
Eligibility Criteria
DISEASE CHARACTERISTICS: Diagnosis of chronic lymphocytic leukemia or Diagnosis of non-Hodgkin's lymphoma Lymphoplasmacytic lymphoma Grade I follicular small cleaved cell lymphoma Grade II follicular mixed cell lymphoma Diffuse small cleaved cell lymphoma Small lymphocytic lymphoma Relapsed after at least 1 course of prior therapy Availability of a 6/6 human leukocyte antigen (HLA) A, B, and DR identical sibling donor Nonmyeloablative transplantation candidate No clinically significant effusions or ascites that would preclude administration of methotrexate PATIENT CHARACTERISTICS: -Age: 18 to 75 Performance status: Eastern Cooperative Oncology Group (ECOG) 0-2 OR Zubrod 0-2 Life expectancy: At least 6 months Hematopoietic: Not specified Hepatic: Bilirubin no greater than 3 mg/dL Renal: Creatinine no greater than 2 mg/dL Cardiovascular: left ventricular ejection fraction (LVEF) at least 40% on multigated acquisition (MUGA) scan or echocardiogram Pulmonary: diffusing capacity of lung for carbon monoxide (DLCO) at least 50% of predicted OTHER: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No uncontrolled bacterial, viral, fungal, or parasitic infection Human Immunodeficiency Virus (HIV)1 and Human Immunodeficiency Virus (HIV)2 negative No other active malignancy except basal cell skin cancer No recent history of drug or alcohol abuse No other primary disease or comorbid illness that would severely limit life expectancy PRIOR CONCURRENT THERAPY Biologic therapy:See Disease Characteristics Biologic therapy:Prior autologous bone marrow transplantation allowed if disease has progressed after transplantation Biologic therapy:No entry on study as part of a tandem autologous transplantation followed by nonmyeloablative allograft protocol Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy:Not specified Surgery: Not specified
Sites / Locations
- Rocky Mountain Cancer Centers
- Delaware Clinical & Laboratory Physicians
- Florida Hospital Cancer Institute
- H. Lee Moffitt Cancer Center and Research Institute
- Blood and Marrow Transplant Group of Georgia
- Holden Comprehensive Cancer Center
- University of Missouri Kansas City School of Medicine
- Hackensack University Medical Center
- St. Joseph's Hospital and Medical Center
- James P. Wilmot Cancer Center
- Oregon Cancer Institute
- University of Pennsylvania Cancer Center
- Kimmel Cancer Center of Thomas Jefferson University - Philadelphia
- Vanderbilt-Ingram Cancer Center
- Simmons Cancer Center - Dallas
- Texas Transplant Institute
- Massey Cancer Center
- University of Wisconsin Comprehensive Cancer Center
- Medical College of Wisconsin
- Ottawa Regional Cancer Centre
- Princess Margaret Hospital
- University of Toronto
- Hopital du Saint-Sacrament, Quebec